Evidence map›Paper›PMID 41664456›Full record

Trial reportAlcohol and alcoholism (Oxford, Oxfordshire)2026

Reductions in cigarette and cannabis use during a randomized clinical trial for alcohol use disorder.

Malia A Belnap, Kaitlin R McManus, Dylan E Kirsch, Erica N Grodin, Lara A Ray

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Alcohol and alcoholism (Oxford, Oxfordshire), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Malia A BelnapNeuroscience Interdepartmental Program, University of California, Los Angeles, 695 Charles E Young Dr S, Los Angeles, CA 90095, United States.ORCID 0000-0002-8160-5524
Kaitlin R McManusDepartment of Psychology, University of California, Los Angeles, 1285 Franz Hall, Box 951563, Los Angeles, CA 90095, United States.
Dylan E KirschDepartment of Psychology, University of California, Los Angeles, 1285 Franz Hall, Box 951563, Los Angeles, CA 90095, United States.ORCID 0000-0001-9935-9635
Erica N GrodinDepartment of Psychology, University of California, Los Angeles, 1285 Franz Hall, Box 951563, Los Angeles, CA 90095, United States.ORCID 0000-0001-5528-4918
Lara A RayDepartment of Psychology, University of California, Los Angeles, 1285 Franz Hall, Box 951563, Los Angeles, CA 90095, United States.ORCID 0000-0002-5734-9444

Funding

A Randomized Controlled Clinical Trial of the Neuroimmune Modulator Ibudilast for the Treatment of Alcohol Use DisorderR01AA026190 · NIAAA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RAY, LARA A. · 2018 to 2021
$2.7M
Doctoral Training in Brain and Behavioral Development During Adolescence (UCLA BBDA)T32HD091059 · NICHD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Mirella Dapretto, ANDREW J FULIGNI · 2018 to 2026
$1.7M
Clinical Neuroscience of Alcoholism: Integrating Neuroscience and Clinical TrialsK24AA025704 · NIAAA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LARA A. RAY · 2018 to 2026
$1.3M
Eunice Kennedy Shriver National Institute of Child Health and Human DevelopmentMediciNova, Inc.NIAAA NIH HHS K24 AA025704NIAAA NIH HHS R01 AA026190NICHD NIH HHS T32 HD091059NIH HHS R01026190 to LARNIH HHS T32HD091059 to MAB
6 · The paper itself

Abstract

objectivesAlcohol, tobacco, and cannabis are the most frequently used psychoactive substances in the United States and are commonly used concurrently. This study analyzed patterns of cigarette and cannabis use during a randomized controlled trial (RCT) for alcohol use disorder (AUD).

methodsThis secondary analysis of a 12-week RCT of ibudilast for AUD (N = 102; 61 M/41F) examined whether cigarette and cannabis use changed over the trial and whether changes in their use were associated with the observed reductions in alcohol consumption.

resultsIndividuals significantly reduced their cigarette use over the trial (P = .002). Cannabis use significantly decreased during the early phase of the trial (P = .006) and subsequently increased during the remainder of the trial (P = .03). Changes in cigarette use and cannabis use were not significantly associated with changes in the primary drinking outcome, percent heavy drinking day (Ps ≥ .22). However, changes in the secondary drinking outcome, drinks per drinking day (DPDD), were positively associated with changes in cigarette use across the trial and negatively associated with changes in cannabis use during the early phase of the trial (Ps < .05).

conclusionIndividuals enrolled in an RCT for AUD were able to reduce their cigarette and cannabis use without being prompted to, and these changes were significantly associated with changes in DPDD. These findings emphasize the importance of evaluating co-occurring substance use in AUD clinical trials, given that significant changes in cigarette and cannabis use behaviors may occur even when not directly targeted.

Indexed as

AlcoholismCigarette SmokingMarijuana SmokingMarijuana UsePyridinesAdultAlcohol DrinkingFemaleHumansMaleMiddle AgedTreatment OutcomePyridinesalcohol use disordercannabis useclinical trialtobacco use

Identifiers

PMID41664456
PMCPMC13157869

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.